









市场行情
/
股票
/
nasdaq-mrus
/

Merus NV

MRUS

96.910USD

+0.010+0.01%

收盘 12/24, 13:00（美东）报价延迟15分钟

7.35B总市值

亏损市盈率 TTM



Merus NV

96.910

+0.010+0.01%

概览公司财务分析

概览

公司

财务

分析

关于 Merus NV 公司

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Merus NV简介



公司代码MRUS

公司名称Merus NV

上市日期May 19, 2016

CEOLundberg (Sven Ante)

员工数量260

证券类型Ordinary Share

年结日May 19

公司地址Yalelaan 62

城市UTRECHT

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Netherlands

邮编3584 CM

电话310302538800

网址https://merus.nl/

公司代码MRUS

上市日期May 19, 2016

CEOLundberg (Sven Ante)

Merus NV公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-15.24%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

Ms. Sherri Spear

Investor Relations and Corporate Communications

Mr. Jason Haddock

Director

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

Mr. Leonard (Len) Kanavy

Non-Executive Independent Director

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

Mr. Gregory D. (Greg) Perry

Chief Financial Officer

Mr. Paolo Pucci

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-15.24%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

Ms. Sherri Spear

Investor Relations and Corporate Communications

Mr. Jason Haddock

Director

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月21日周日

持股股东

股东类型

持股股东

占比

Genmab A/S

94.86%

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

持股股东

占比

Genmab A/S

94.86%

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

股东类型

持股股东

占比

Corporation

96.78%

Hedge Fund

40.76%

Investment Advisor/Hedge Fund

29.65%

Investment Advisor

15.32%

Research Firm

2.54%

Private Equity

1.78%

Venture Capital

1.47%

Bank and Trust

0.65%

Pension Fund

0.64%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

434

77.32M

101.98%

-5.60M

2025Q2

411

75.46M

99.77%

-10.50M

2025Q1

420

74.82M

101.12%

-10.15M

2024Q4

398

74.69M

108.18%

-7.45M

2024Q3

373

72.99M

107.03%

-6.71M

2024Q2

355

69.91M

103.77%

+7.77M

2024Q1

315

57.35M

97.63%

-5.32M

2023Q4

282

57.36M

99.41%

-5.55M

2023Q3

268

57.60M

100.50%

+2.76M

2023Q2

260

49.90M

100.83%

+114.35K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Paradigm BioCapital Advisors LP

4.28M

5.65%

+727.89K

+20.48%

Jun 30, 2025

Avoro Capital Advisors LLC

3.16M

4.16%

+155.56K

+5.19%

Jun 30, 2025

Commodore Capital LP

3.52M

4.65%

-947.84K

-21.19%

Jun 30, 2025

Deerfield Management Company, L.P.

3.38M

4.47%

+210.70K

+6.64%

Jun 30, 2025

Westfield Capital Management Company, L.P.

2.04M

2.69%

+541.17K

+36.05%

Jun 30, 2025

RTW Investments L.P.

4.00M

5.28%

-168.84K

-4.05%

Jun 30, 2025

Fidelity Management & Research Company LLC

6.22M

8.2%

+593.98K

+10.56%

Jun 30, 2025

Woodline Partners LP

1.54M

2.04%

+142.73K

+10.19%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

AltShares Merger Arbitrage ETF

3.3%

NYLI Merger Arbitrage ETF

3.1%

ALPS Medical Breakthroughs ETF

2.89%

Goldman Sachs Hedge Industry VIP ETF

2.75%

ProShares Merger ETF

2.74%

First Trust IPOX Europe Equity Opportunities ETF

2.61%

Tema Oncology ETF

2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

1.4%

Harbor Health Care ETF

1.29%

AltShares Event-Driven ETF

1.23%

AltShares Merger Arbitrage ETF

占比3.3%

NYLI Merger Arbitrage ETF

占比3.1%

ALPS Medical Breakthroughs ETF

占比2.89%

Goldman Sachs Hedge Industry VIP ETF

占比2.75%

ProShares Merger ETF

占比2.74%

First Trust IPOX Europe Equity Opportunities ETF

占比2.61%

Tema Oncology ETF

占比2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.4%

Harbor Health Care ETF

占比1.29%

AltShares Event-Driven ETF

占比1.23%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Merus NV的前五大股东是谁？



Merus NV 的前五大股东如下：
Paradigm BioCapital Advisors LP持有股份：4.28M，占总股份比例：5.65%。
Avoro Capital Advisors LLC持有股份：3.16M，占总股份比例：4.16%。
Commodore Capital LP持有股份：3.52M，占总股份比例：4.65%。
Deerfield Management Company, L.P.持有股份：3.38M，占总股份比例：4.47%。
Westfield Capital Management Company, L.P.持有股份：2.04M，占总股份比例：2.69%。